Salix Pharmaceuticals

Valeant Withdraws Prior Guidance, Announces CEO Mike Pearson Will Return To Work Immediately Following Pneumonia Scare

Viking Global's Shareholder Letter Talks New Positions In Google, Cheniere, Biggest Winners & Losers

U.S. Produced Fewer Than Expected Jobs In October

Viking Global's Shareholder Letter Talks New Positions In Google, Cheniere, Biggest Winners & Losers

U.S. Produced Fewer Than Expected Jobs In October

Will Actavis Win Competition For Allergan's Affection?

#PreMarket Primer: Wednesday, September 24: US Economy Looking Strong In The Third Quarter

Will Actavis Win Competition For Allergan's Affection?

#PreMarket Primer: Wednesday, September 24: US Economy Looking Strong In The Third Quarter

#PreMarket Primer: Tuesday, September 23: First Airstrikes In Syria Begin

Cramer's Watchlist: Target And Lowe's Rebound As Hertz Remains In The Red

Salix Pharmaceuticals Recent News

Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs

5 Drug Companies Profiting From Generics

Dow Flirts With 17,000, S&P 500 Inches Closer To 2,000 In First Trading Day Of The Third Quarter

UPDATE: Piper Jaffray Raises PT on Salix Pharmaceuticals from $47 to $50

UPDATE: Duncan-Williams Color on Salix Pharmaceuticals Upgrade

Duncan Williams Upgrades Salix Pharmaceuticals To Buy, $47 PT

Piper Jaffray Reiterates Overweight Rating On Salix Pharmaceuticals

Duncan-Williams Maintains Buy Rating On Salix

UPDATE: Piper Jaffray Color On SLXP Target Increase

Piper Jaffray Raises PT on Salix Pharmceuticals To $42

Piper Jaffray Reports Salix Pharmaceuticals Not Alarmed By NEJM Letters

Jefferies Maintains Buy on Salix Pharmaceuticals (SLXP)

Piper Jaffray Lowers PT On Salix Pharmaceuticals To $39

Goldman Sachs Maintains Buy on Salix Pharmaceuticals (SLXP)

Piper Jaffray Reiterates Overweight on Salix Pharmaceuticals (SLXP)

Piper Jaffray Reiterates OW Rating, $60 PT On SLXP

Salix Pharmaceuticals, Inc. and the Colon Cancer Alliance Announce Colonoscopy For Dummies® is Now Available for Free Download

Goldman Sachs Initiates Coverage on Salix Pharmaceuticals (SLXP)

Favorable Update From Salix Pharmaceuticals

Piper Jaffray Reiterates Salix Pharmaceuticals (SLXP) Overweight Rating

Oppenheimer Maintains Salix Pharmaceuticals (SLXP) Outperform Rating

Salix Pharmaceuticals (SLXP) Shares Up Nearly 20%